Johnson & Johnson (JNJ) Profit After Tax Growth (3y) (2012 - 2026)
Johnson & Johnson (JNJ) Profit After Tax Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
PAT Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
76.51% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
133.08% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
42.47% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
19.53% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-51.87% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-13.81% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
26.01% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
75.17% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
-6.24% |
| Date | Value |
|---|
| Mar 29, 2026 |
133.08% |
| Dec 28, 2025 |
16.60% |
| Sep 28, 2025 |
4.94% |
| Jun 29, 2025 |
9.12% |
| Mar 30, 2025 |
34.00% |
| Sep 29, 2024 |
-9.77% |
| Jun 30, 2024 |
-9.29% |
| Mar 31, 2024 |
-19.32% |
| Dec 31, 2023 |
32.57% |
| Oct 1, 2023 |
6.63% |
| Jul 2, 2023 |
14.03% |
| Apr 2, 2023 |
-27.75% |
| Jan 1, 2023 |
-6.99% |
| Oct 2, 2022 |
36.50% |
| Jul 3, 2022 |
-8.74% |
| Apr 3, 2022 |
6.83% |
| Oct 3, 2021 |
-2.32% |
| Jul 4, 2021 |
16.66% |
| Apr 4, 2021 |
12.37% |
| Jan 3, 2021 |
29.31% |
